Literature DB >> 28329487

Apremilast for the treatment of psoriatic arthritis.

Brent C Martin, Logan W Thomas1, Francis J Dann.   

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatoryarthropathy that affects joints and entheses andis associated with psoriasis (PsO). There are fiveclinical patterns of PsA: symmetrical polyarthritis,distal interphalangeal arthropathy, asymmetricaloligoarthritis, arthritis mutilans, and spondylitis, withor without sacroiliitis. Concerning PsA, the goals oftherapy are to control inflammation, prevent articulardamage, and reduce discomfort in the affected joints.Although there are many therapeutic options forthe treatment of PsAs, physicians most often beginwith nonsteroidal anti-inflammatory drugs (NSAIDs)for mild disease. Disease-modifying anti-rheumaticdrugs (DMARDS) are reserved for moderate to severedisease. Apremilast may be a useful option for somepatients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28329487

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  1 in total

1.  Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

Authors:  Kurt de Vlam; Adrien Nzeusseu Toukap; Marie-Joëlle Kaiser; Johan Vanhoof; Philip Remans; Marthe Van den Berghe; Silvana Di Romana; Filip Van den Bosch; Rik Lories
Journal:  Adv Ther       Date:  2022-01-03       Impact factor: 3.845

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.